Zhenhui Xu

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Replacement Therapy

Atopic Dermatitis

Top Venues

Dermatology and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Jonathan Ian Silverberg, Andreas Wollenberg, Linda F Stein Gold, James Q Del Rosso, Gil Yosipovitch, Peter A Lio, Y José Manuel Carrascosa, Gaia Gallo, Yuxin Ding, Zhenhui Xu, Marta Casillas, Evangeline J Pierce, Helena Agell, Pamela Guglielmini
Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment. Dermatology and therapy 14 (8) (2024)
Jonathan Ian Silverberg, Andreas Wollenberg, Linda F Stein Gold, James Q Del Rosso, Gil Yosipovitch, Peter A Lio, Y José Manuel Carrascosa, Gaia Gallo, Yuxin Ding, Zhenhui Xu, Marta Casillas, Evangeline J Pierce, Helena Agell, Pamela Guglielmini
Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment. Dermatology and therapy 14 (8) (2024)
Jonathan Ian Silverberg, Andreas Wollenberg, Linda F Stein Gold, James Q Del Rosso, Gil Yosipovitch, Peter A Lio, Y José Manuel Carrascosa, Gaia Gallo, Yuxin Ding, Zhenhui Xu, Marta Casillas, Evangeline J Pierce, Helena Agell, Pamela Guglielmini
Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment. Dermatology and therapy 14 (8) (2024)
Jonathan Ian Silverberg, Andreas Wollenberg, Linda F Stein Gold, James Q Del Rosso, Gil Yosipovitch, Peter A Lio, Y José Manuel Carrascosa, Gaia Gallo, Yuxin Ding, Zhenhui Xu, Marta Casillas, Evangeline J Pierce, Helena Agell, Pamela Guglielmini
Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment. Dermatology and therapy (2024)